PREPARATION FOR IMMUNOASSAY AND METHOD FOR PRODUCING THE PREPARATION

Abstract: A simple, quick and inexpensive method for producing a highly purified ligand for use in immunoassays comprises, according to the invention, the use of antigens and their corresponding antibodies and a covalent or non-covalent binding to a solid support, under which antigens and antibodies are present in dissociated form. These antigens and antibodies are separated from irrelevant molecules, which separation may take place prior to the application to the surface. The immunoprecipitate is then dissociated into antigen and antibody prior to the coating of the surface and coupled so that qualities are preserved after reestablishment of the physiological conditions in the liquid environment around the bound components. The antibodies can be selected for affinity and/or avidity expressed as dissociability prior to the coating of the surface.

Description: PREPARATION FOR IMMUNOASSAY AND METHOD FOR PRODUCING THE PREPARATION. The invention relates to a preparation for immunoas- say consisting of a solid support, to which two li- gands are linked, and to a method for producing the preparation. Immunoassays are among other things used for quanti¬ tatively and qualitatively measuring a single compo¬ nent, such as antigens or antibodies in a complex li¬ quid, such as blood fractions, secretions, tissue extracts, plant sap, cultures of bacteria, food ex- tracts and similar liquids. Antibodies linked to a solid surface are used in many of these assays. As an indicator for example iso¬ topes, enzymes, fluorochromes, which may be bound to specific antigens, can be used. For the assay are used balanced amounts of surface bound components and soluble components together with a suitable indicator. During the production of surface based assays the primary binding or coating to the surface forms an essential part of the method, in that all the basic properties of the assay depend on particularly the purity of the active component in the coating mixture and of the strength of the bond between the components linked to the surface and the specific complementary components in soluble form in the sub¬ sequent immunoassay. Concerning the purity or the relative amount of foreign components in the coating mixture which at the same time are capable of attaching themselves to the solid support, these components will compete with the specific component for the available binding sites on the surface. Since in practice it is difficult to obtain a speci¬ fic component of high purity, this will cause a correspondingly large proportion of the binding sites to be occupied by foreign components. This again in¬ volves the risk that these components will perform an unspecific adsorbent property against components in soluble form in the subsequent immunoassay, which will increase the inaccuracy and background noise in the assay, Concerning the strength of the bond between the sur¬ face bound antibodies and the subsequently added an- tigens in soluble form, the use of a surface bound antibody in an assay will mean that the efficiency of this antibody as expressed by the affinity of the bond will be decisive for the subsequent process steps. A selection of antibodies with high affinity is in practice very difficult to perform with the known immunospeσific technology. Moreover, the type of antibody is decisive since there is a distinction between polyclonal and mono- clonal antibodies. The affinity distribution or avi¬ dity of polyclonal antibodies may vary from one pre¬ paration to the other from the same as well as from different animals. Monoclonal antibodies always have the same affinity which will often be insufficient, i.e. of average or low affinity. Monoclonal antibodies are furthermore very expensive to develop and produce in large quan- tities. In the production of immunoassays the purity and strength of the bond of the ligand is decisive for the other characteristics of the assay, such as pro- cess time, accuracy and sensitivity. The use of irαmunocomplexes for the production of an¬ tigen or antibody linked to a solid support has pre¬ viously been described in EP published specification no. 80,108 and EP published specification no. 80,109. The latter publication, describes a process,- by which immunocomplexes formed in vivo can be analyzed by initial dissociation and binding to a solid support. Pathogen immunocomplexes formed in vivo is an ex- tremely heterogeneous mixture, in which there is a multiple of antibody specificities against a large number of components against which the patient shows immunoreaction. It is moreover known that to these immunocomplexes are bound a number of serum proteins of biological importance, e.g. serum complement fac¬ tors. All together these in vivo formed immunocom¬ plexes are a poorely defined unit. Their production in pure form is carried out by means of e.g. precipi¬ tation with low concentrations of polyethylene glycol or by binding on a solid support to Clq or protein A. The purpose of the present invention is not to ana¬ lyze the composition of immunocomplexes formed in vi¬ vo, but merely to provide a fully quantitative immu- nochemical measuring tool. The immunoprecipitates of the present invention are thus well-defined at a num¬ ber of levels in that they are produced in vitro from monospecific antibody with well-defined titer, and besides measures have been taken to prevent attach- ment of contaminating serum complement factors, etc. EP published specification no. 80,108 describes the detection of antigen by means of components of immu¬ nocomplexes linked to solid supports, so that antigen and antibody no longer have the form of immunocom¬ plexes but are linked separately to the solid sup¬ port. The present invention, however, aims at an in¬ complete dissociation of the immunoprecipitates so that apart from the binding to the solid support, a well-defined population of small immunoaggregates with high antibody activity is" provided. This method has turned out td increase the binding capacity of the surface considerably for the complementary anti¬ gen. Graduated dissociation tests have shown that the antibody activity which can be released at extreme pH-values, i.e. close to pH 2.5 and pH 12.0 is found as incompletely dissociated immunoaggregates and that there is an optimum size for these in relation to the use in immunoassays. These immunoaggregates have turned out to function better than free and totally dissociated antibodies. The present invention de¬ scribes a process which selects immunoaggregates both with regard to size and average antibody binding force. The pH-conditions mentioned in the present example used during the dissociation do not form a general recipe in that individual adjustments may be necessary from one measuring system to the other. Species of animal ' and molecular size are important parameters and certain immunization methods create antibodies which possess very low avidity and have little tendency to form optimum immunopreσipitations for the present purpose. To summarize, it can be concluded that an effective and immunospecifiσ purification of antibody makes the process more expensive. Consequently, antibody prepa¬ rations are often used which are purified by physi¬ cal/chemical methods, such as salt precipitation and ion exchange chromotography. Such preparations are free from the main component of globulins but still contain between 95% and 99% of inactive and irrele¬ vant antibodymolecules which may take up a lot of room on the surface. In many immunoassays these inactive antibody frac¬ tions cause-an unwanted unspe,σific adsorption of ir¬ relevant molecules from the applied solutions. This therefore increases the background signal and produ- ces a reduced signal to noise ratio. As mentioned earlier, immunospecific purification of the components for use as ligand is a very expensive procedure, if at all possible in practice. Particularly, immunospecific purification of an anti¬ body with a high affinity and avidity is difficult because of the very strong antigen-antibody binding. The cleavage of these bonds requires the use of very powerful dissociation means which are known for having a denaturating effect on many types of compo¬ nents. In solid-phase immunosorbent systems an insolubilized antigen will often lose its reactivity during the elution procedure whereas the antibody will not. This means that the adsorbent can only be used a few times or will be useless for the purification of the cor- responding antibody. In liquid-phase systems the separation of the disso¬ ciated antigen and antibody from each other by known physical-chemical separation methods will often in- volve a number of problems. It is the object of the present invention to overcome these shortcomings and disadvantages of the known method, and this is achieved by a preparation for im- munoassay consisting of a solid support, to which two ligands are linked, as referred to in the" pre¬ amble of claim 1, and by a method for producing said preparation, as referred to in the preamble of claim 2, said preparation being characterized in that the two ligands are an antigen and the corresponding mo¬ nospecific antibody, and that the two ligands origi¬ nate from a well-defined immunoprecipitate produced in vitro from an antigen solution and an animal-de¬ rived antibody, and a method being characterized in that antigen and antibody from a well-defined immu¬ noprecipitate are used as antigen and antibody, and that the immunoprecipitate is in a partially dis¬ sociated form during the binding to the solid support in the form of small and highly active immunoaggre- gates. Hereby is obtained a preparation and a simple and inexpensive method for producing a highly purified ligand for use in immunoassays while it at the same time becomes possible by using antibodies with hete- rogenous bond strength prior to the coating to per¬ form a reproducible selection of antibodies with a defined bond strength, independently of the composi- tion of the initial antibody. Add to this a considerable increase in the binding capacity of the surface for the specific antigen, which in turn provides large reduction of the process time for the immunσassay and provides a higher degree of accuracy of the assay. This is due i.a. to in¬ creased density of the specific ligand on the surface in question. In the following the invention will be described in closer detail by describing the steps of the assay. The formation of sedimentable immunoprecipltates which is a molecular complex between antibodies and their corresponding antigens from soluble antigen and antibody takes place in accordance with the generally known precipitin reaction. Antigen is taken to mean protein, nucleic acid, polysaccharide, hapten and cell, and by antibody is meant immunocompound or im- munoglobulins from any species of animal. The concept of antibody includes polyclonally produced antibodies as well as monoclonally produced antibodies, monoclo¬ nal antibodies, however, often requiring two or more clone products in order to achieve a precipitation. The optimum reaction is found at or close to the "point of equivalence", where antigen as well as an¬ tibody is quantitatively used in the formation of the immunoprecipitate. The optimum ratio between antigen or antibody can be established for instance by weigh- ing or by nitrogen determination on the washed preci¬ pitate. Simpler methods comprise turbidimetry, nephe- lometry or visual inspection of milky precipitations. Isolation of insoluble immunoprecipitates formed in the liquid phase can take place by simple centrifu- ging and several washes. The ability of the complexes to adsorb complement factors will cause a contamina¬ tion which can be reduced by adding complement-σonsu- ming reagents prior to the actual precipitation. A partial blocking of the binding of complement factors can be achieved by adding EDTA. Dissociation of the immunoprecipitate, meaning any i- nfluence which is capable of partially dissociating the bond between antibodies and their corresponding antigens, such as high temperature, high ion strength, high pH, low pH, impact of particular ions (e.g. chaotropiσ ions) and competitive molecules. This dissociation thus takes place at high tempera¬ ture, high or low pH, influence of particular ions such as chaotropic ions and competitive molecules. Analyses have shown that dissociation at a high pH is best suited for the present purpose. At this stage a selection of small immunoaggregates containing antibodies with a high binding force is also made. By pre-dissoσiating under comparatively mild dissociation conditions, it is achieved that on- ly the weakest antibody bonds are dissociated, where¬ after soluble antibodies, antigens and immu¬ noaggregates can be decanted after centrifuging at low G-number. The pellet will largely consist of me¬ dium to highly associated immunoprecipitates which can be partially separated by an effective dissocia¬ tion means and be used for the coating, of a surface in the following stage in the form of small im¬ munoaggregates with high antibody activity. 5 This step comprises binding of the components, i.e. antigens or antibodies, to a solid support, which may take place by both covalent as well as non-covalent forces. Common to the methods is that the physical- 10 chemical environment in which the process takes place makes it possible for the antigen and the cor¬ responding antibody to remain partially dissociated during the binding to the surface in order for the aggregates to become fixed side by side to this. 15 Binding of molecules to a solid support can take- place by , means of both covalent as well as non-σqva- lent forces. The surface may be in the nature of a plastic surface, e.g. polystyrene, or be composed of 20 polymeric material of a different kind, such as cel¬ lulose. The support can also consist of other materi¬ als possessing the quality that a molecule or a com¬ ponent can be adsorbed or linked thereto, either on the basis of the surface structure or on the basis of 25 chemically reactive groups introduced thereon. Example 1 The construction of competitive ELISA for HPL (Human 30 Placental Laσtogen) in serum from pregnant women. JJ> This assay is based on the coupling of immunoprecipi¬ tates formed between human placental lactogen and an- ti-HPL-antibody from sheep. After the coupling, HPL as well as anti-HPL is reactive to the complementary soluble component. An enzyme is used as an indicator principle. In the assay the patient sample containing the unknown amount of HPL is mixed with a defined amount of enzyme conjugated HPL of high purity. After mixing, a volume thereof is transferred to a hole in a polystyrene microtitre tray (NUNC immunoplate), which prior to this has been coated with partially dissociated HPL-anti-HPL immunoprecipitates. Enzyme conjugated HPL and Patient-HPL will then compete for the accessible binding sites on the anti-HP -antibo¬ dies on the plastic surface and bind themselves to this corresponding to their relative concentration. The concentration of HPL in the patient sample will be inversely related to the insolubilized enzyme ac¬ tivity. • By the present technique it was found that the total process time for the assay could be reduced to less than 60 minutes. By using fully automatic equipment the reaction time could be further reduced. It became possible to mesure from 0.5-20 micrograms/ml in the very same assay, i.e. that the described method pro¬ vided a much wider measuring range compared with that of other methods. Higher sensitivity could be obtain¬ ed but was not desired for clinical reasons. Description of the procedure for the coupling of dis¬ sociated HPL-anti-HPL complexes. I. The formation of immunoprecipitates. The antigen mixture consists of a crude HPL-contain- ing extract of placenta which was produced as fol- lows: 1 placenta was homogenized for 5 minutes in the presence of 500 ml 0.1 M phosphatebuffered saline, pH 7.4. Solid pieces of tissue were removed by σentri- fuging at 1000 G for 5 minutes. Cell organelles and the like were removed by further centrifuging at 50000 G for 15 minutes. EDTA was added to a final concentration of 10 mM. In order to find the optimum ratio between antigen and antibody, a simple floccu- lation test was instituted, in which variable volumes of the antigen preparation was mixed with variable volumes of the antibody preparation, e.g.: glass No. : 1 2 3 4 5 Crude placenta extract 50 100 200 400 1000 (μl) Monospec. antibody 1000 400 200 100 50 (μl) The formation of milky precipitates was observed, and the optimum ratio between antigen and antibody was selected corresponding to the first glass with vi- sible precipitates. II. Isolation Of immunoprecipitates from non-reactive material was carried out by centrifuging 4 times (1000 G for 10 minutes) and washing with 1 M NaCl. III. Selection. Of high-avidity antibodies was carried out by pre- dissociating and removing weakly binding antigen-an¬ tibody complexes in a 0.1 M NaOH-boratebuffer, pH 11.0. The non-dissociated immunoprecipitates were isolated by centrifuging at 10000 G for five minutes. Partial dissociation of strongly binding immunopre¬ cipitates took place by suspending these in a 0.1 M NaOH-boratebuffer, pH 12.0 - 12.2 for 15 minutes at room temperature. Further dilution then takes place with a 0.1 M NaOH-boratebuffer, pH 11.4, so that the final protein concentration was approx 1 microgram per ml. pH was adjusted to 11.6, and the coating mix¬ ture was ready after 15 minutes standing at room tem¬ perature. IV. Surface treatment. As solid support for coating was used polystyrene mi- crotitre trays (NUNC F 16 modules, high binding). 200 microliters of coating mixture were added to each microtitre well and incubated 4-15 ' hours at room tem¬ perature in a moisture-proqf box. The wells .were washed twice with 0.01 M citric acid buffer, pH 2.3, with 0.02% Tween 20 added, followed by 2 x washing with 0.01 M tris-buffered saline added (0.14 M NaCl) with 0.1% NaN 3 and 0.02% Tween 20 added. The coated microtitre trays were then ready for use. Example 2 The above example describes a competitive measuring construction. The advantages of the coupling method can also be used for the sandwich method (double an¬ tibody method). In this assay construction, account must be taken of the presence of immunoreactive an¬ tigen on the surface, which is coupled side by side with the corresponding antibody, it is assumed that the molecule X should be quantitized in serum. This molecule can be cleaved enzymatically in two or seve- ral well-defined fragments XI, X2 and X3. Presumably, these fragments can be separated from each other by known separation methods, and thus monospecific anti¬ bodies against them can also be produced. A sandwich method can then be initiated by forming immunopreci¬ pitates between XI and anti-Xl, followed by coupling of these to a support. Monospecific antibodies against either X2 or X3 can then be used as a secon¬ dary indicator-reagent, provided these are conjugated with an indicator principle. Antibodies against X2 or X3 will not react with the insolubilized Xl-antigens. Example 3 With the present technology both competitive and sandwich immunoassays can be constructed so that the antigen component rather than the antibody can be used as the primary ligand, however with the li¬ mitation that epitopes can be lost, while new ones will emerge when the dissociation agent influences the antigen.

Claims: P A T E N T C L A I M S 1. Preparation for immunoassay consisting of a solid support, to which two ligands are linked, c h a ¬ r a c t e r i s e d in that the two ligands are an antigen and the corresponding monospecific antibody, and in that the two ligands originate from a well-de¬ fined immunoprecipitate produced in vitro from an an¬ tigen solution and an animal-derived antibody. 2. Method for producing a preparation according to claim 1, c h a r a c t e r i s e d in that an anti¬ gen and an antibody originating from a well-defined immunoprecipitate is used as antibody, and that the immunoprecipitate exists in a partially dissociated form during the binding to the solid support in the form of small.and highly active immunoaggregates. 3. Method for producing a preparation according to claim 2, c h a r a c t e r i s e d in that the im¬ munoprecipitate is purified by a generally known im¬ munospecific procedure. 4. Method for producing a preparation according to claim 2 or 3, c h a r a c t e r i s e d in that the immunoprecipitate is pre-dissociated so that the im¬ munoprecipitate is separated in an easily soluble part largely consisting of free antigens and antibo¬ dies with weak binding force, and a sparingly soluble part consisting of strongly associated immu¬ noaggregates with largely strongly binding antibo¬ dies, and that the latter are used for subsequent binding to the solid support. 5. Method according to claims 2-4, where the method is used for immunochemical detection of an antigen in a sample, c h a r a c t e r i s e d in that compo¬ nents linked to a solid support are used as described in claims 1-4.

Inventors: FOLKERSEN J RGEN, FOLKERSEN, JRGEN
Applicants: IMMUNTECH AS, IMMUNTECH A/S
Application year: 1987
Main classification: G01N33
IPC codes: G01N33